A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
This study is testing a medication called Migalastat (a 20 mg capsule) for children aged 2 to 11 who have Fabry disease. Specifically, it's for those with a particular genetic change that Migalastat is known to help. We want to see how safe the medicine is, how the body uses it (pharmacokinetics), what effects it has (pharmacodynamics), and if it improves the health of children with Fabry disease. The study will last for about 12 months of treatment, with an option to continue afterwards. Children joining can't have been on other Fabry treatments recently or must have stopped them. This research hopes to find a safe and effective way to manage Fabry disease in a younger age group.
De un vistazo
¿De qué trata este estudio?
Fabry disease is a rare genetic condition that can affect many parts of the body, including the kidneys, heart, and skin. It happens because the body can't make enough of a certain enzyme, which leads to a build-up of fats in cells. This can cause various health problems.
This study is looking at a medicine called Migalastat. It's designed for children aged 2 to under 12 years old who have Fabry disease, but only if they have a specific type of genetic change that Migalastat is known to work for. Think of it like a key fitting a specific lock. The main goal is to understand how safe the medicine is for these younger children, how their bodies process it, and if it helps to improve their Fabry disease symptoms over about a year.
By carefully studying Migalastat in this age group, researchers hope to gather important information that could potentially lead to it becoming a treatment option for more children with Fabry disease in the future. This is a common and important step in developing new medicines.
Puntos clave
- This study evaluates Migalastat for children (2-11 years) with Fabry disease.
- It focuses on specific genetic types of Fabry disease that Migalastat can help.
- The study assesses safety, how the body handles the medicine, and its effectiveness.
- Treatment lasts about 12 months, with an option for longer-term follow-up.
- Children currently on other Fabry treatments may need to pause them before joining.
¿Quién puede ser elegible?
This study is for boys and girls with Fabry disease who are between 2 and 11 years old. A very important part of joining is that your child must have a specific type of genetic change (called an 'amenable GLA variant') that Migalastat is designed to work with. Your child should also have experienced at least one medical issue related to their Fabry disease.
Children can't join if they have severe kidney problems or are already on dialysis. Also, if your child has an allergy to Migalastat or similar medicines, or if they are currently taking other research medicines, they wouldn't be able to participate. If your child has had gene therapy, they also can't take part. Girls and boys who are able to have children must agree to use birth control during the study and for 30 days afterwards.
Additionally, if your child has recently received (within the last 14 days) or is currently receiving other specific Fabry disease treatments like enzyme replacement therapy (ERT), they would need to stop that treatment for the required time before joining.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Is your child between 2 and 11 years old?
- Does your child have Fabry disease with a specific genetic change that Migalastat works for?
- Has your child had any health problems linked to Fabry disease?
- Does your child NOT have severe kidney problems or an allergy to Migalastat?
- Has your child NOT received gene therapy at any point?
¿En qué consiste la participación?
If your child joins, they will take Migalastat as a capsule. The study involves two treatment periods totaling about 12 months, followed by an option to continue on the medicine in an extension phase. There will be no breaks in treatment between these active phases. If your child stops taking part at any time, they will have a safety check-up 30 days later.
Throughout the study, your child will have regular visits to the clinic for medical checks. This will include blood tests to measure the level of Migalastat in their body at certain times. These blood tests are done at specific points, including four samples over a 24-hour period within the first month, and then single samples at months 6 and 12. These tests help the doctors understand how the medicine is working and how safe it is. The total duration of active treatment for initial participation is about 12 months.
Riesgos y beneficios potenciales
Ubicaciones (12)
- Emory GeneticsCódigo postal verificadoAtlanta, Estados Unidos· Reclutamiento
- University of Minnesota Masonic Children's HospitalCódigo postal verificadoMinneapolis, United States· Reclutamiento
- Atrium Health Levine Children's HospitalCódigo postal verificadoCharlotte, United States· Reclutamiento
- Cincinnati Children's Hospital Medical CenterCódigo postal verificadoCincinnati, Estados Unidos· Reclutamiento
- Hospital Infantil UPMC de PittsburghCódigo postal verificadoPittsburgh, Estados Unidos· Reclutamiento
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.Código postal verificadoFairfax, United States· Reclutamiento
- Universitair Ziekenhuis (UZ) LeuvenCódigo postal verificadoLovaina, Bélgica· Reclutamiento
- Universitäetsklinikum Müenster (UKM) Klinik für Kinder- und Jugendmedizin - Allgemeine PaediatrieCódigo postal verificadoMünster, Germany· Reclutamiento
- Kitasato University HospitalCódigo postal verificadoSagamihara, Japan· Reclutamiento
- Hospital Universitario de la PazCódigo postal verificadoMadrid, España· Reclutamiento
- Great Ormond Street Hospital for Children NHS Foundation TrustCódigo postal verificadoLondres, Reino Unido· Aún no reclutando
- Fundación del NHS de la Universidad de ManchesterCódigo postal verificadoManchester, Reino Unido· Reclutamiento
Preguntas comunes
What is Fabry disease?
Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, leading to their build-up in cells and causing health problems in various organs.
What is Migalastat?
Migalastat is a medication that helps the body's own faulty enzyme work better in some people with Fabry disease who have a specific genetic change.
¿Cuánto tiempo estará mi hijo en el estudio?
Your child will receive Migalastat treatment for about 12 months, with the possibility of continuing in an extension phase afterwards.
Will my child have to stop their current Fabry treatment?
If your child is on enzyme replacement therapy (ERT), they would need to stop it at least 14 days before starting this study.
Can my child choose to leave the study?
Yes, you can choose to withdraw your child from the study at any time without having to give a reason, and it won't affect their future medical care.
Cómo obtener más información
Amicus Therapeutics Patient Advocacy
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.